硼替佐米治疗复发经典型霍奇金淋巴瘤患者的经验。 - Suppr

Suppr

超能文献

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.

作者信息

Younes Anas, Pro Barbara, Fayad Luis

出版信息

Blood. 2006 Feb 15;107(4):1731-2. doi: 10.1182/blood-2005-09-3731.

DOI:10.1182/blood-2005-09-3731

PMID:16461762

Abstract

摘要

相似文献

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.

Blood. 2006 Feb 15;107(4):1731-2. doi: 10.1182/blood-2005-09-3731.

The role of bortezomib in the treatment of lymphoma.

Cancer Invest. 2007 Dec;25(8):766-75. doi: 10.1080/07357900701579570.

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.

Br J Haematol. 2009 Nov;147(4):531-4. doi: 10.1111/j.1365-2141.2009.07875.x. Epub 2009 Sep 1.

Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.

Br J Haematol. 2012 Jul;158(2):290-292. doi: 10.1111/j.1365-2141.2012.09137.x. Epub 2012 Apr 26.

Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.

Oncology. 2010;79(3-4):247-54. doi: 10.1159/000322866. Epub 2011 Mar 3.

Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting.

Leuk Lymphoma. 2013 Jan;54(1):209-11. doi: 10.3109/10428194.2012.701741. Epub 2012 Aug 13.

Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.

Leuk Lymphoma. 2013 Mar;54(3):497-502. doi: 10.3109/10428194.2012.722215. Epub 2012 Sep 11.

Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.

Leuk Res. 2009 Sep;33(9):e170-2. doi: 10.1016/j.leukres.2009.03.036. Epub 2009 Apr 28.

Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.

Leuk Lymphoma. 2013 Nov;54(11):2563-4. doi: 10.3109/10428194.2013.780289. Epub 2013 Apr 19.

Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.

Haematologica. 2006 Jun;91(6):837-9.

引用本文的文献

Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Target Oncol. 2023 Sep;18(5):685-695. doi: 10.1007/s11523-023-00992-4. Epub 2023 Aug 26.

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.

Leukemia. 2017 Mar;31(3):602-613. doi: 10.1038/leu.2016.238. Epub 2016 Aug 19.

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.

Leuk Lymphoma. 2016 Feb;57(2):445-447. doi: 10.3109/10428194.2015.1032966. Epub 2015 Mar 25.

The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.

Br J Haematol. 2013 Sep;162(5):657-69. doi: 10.1111/bjh.12452. Epub 2013 Jul 4.

Novel therapies for Hodgkin Lymphoma.

Ther Adv Hematol. 2010 Feb;1(1):23-9. doi: 10.1177/2040620710387980.

Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.

Oncologist. 2012;17(3):367-76. doi: 10.1634/theoncologist.2011-0258. Epub 2012 Mar 2.

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future.

Adv Hematol. 2011;2011:865870. doi: 10.1155/2011/865870. Epub 2011 Apr 6.

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances.

Genome Med. 2011 Apr 28;3(4):26. doi: 10.1186/gm240.

Recent advances in anti-angiogenic therapy of cancer.

Oncotarget. 2011 Mar;2(3):122-34. doi: 10.18632/oncotarget.234.

Beyond chemotherapy: new agents for targeted treatment of lymphoma.

Nat Rev Clin Oncol. 2011 Feb;8(2):85-96. doi: 10.1038/nrclinonc.2010.189. Epub 2010 Dec 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验